Natera Inc NTRA

NAS: NTRA | ISIN: US6323071042   18/09/2025
179,86 USD (+2,53%)
(+2,53%)   18/09/2025

22 januari 2024 · Invitae Completes Sale of Reproductive Health Assets to Natera · Persbericht

21 oktober 2023 · NATERA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Natera, Inc. - NTRA · Persbericht

9 december 2022 · Natera Announces Publication of Multi-Center Study Validating Signatera's Ability to Predict Recurrence in Esophageal and Gastric Cancers · Persbericht

7 december 2022 · Natera to Present New Signatera™ and Empower™ Data at the 2022 Annual San Antonio Breast Cancer Symposium · Persbericht

6 december 2022 · Natera Announces Publication of Clinical Experience Study with 18,984 Twin Pregnancies Supporting Excellent Performance of Panorama™ NIPT · Persbericht

23 november 2022 · Natera to Participate in the Piper Sandler 34th Annual Healthcare Conference · Persbericht

21 november 2022 · New Published Study Further Demonstrates the Ability of Natera's mPCR Technology to Monitor Immunotherapy Response in Metastatic Uveal Melanoma Patients · Persbericht

16 november 2022 · Natera Announces Pricing of Follow-On Offering · Persbericht

15 november 2022 · Natera Launches Proposed Follow-On Offering · Persbericht

8 november 2022 · Natera Reports Third Quarter 2022 Financial Results · Persbericht

2 november 2022 · Natera Awarded National MRD Testing Contract by the U.S. Department of Veterans Affairs · Persbericht

1 november 2022 · Natera to Participate in Credit Suisse 31st Annual Healthcare Conference · Persbericht

1 november 2022 · Natera to Report its Third Quarter 2022 Results on November 8th · Persbericht

6 oktober 2022 · New Publication Validates Performance of Natera's Signatera™ MRD Test in Ovarian Cancer · Persbericht

4 oktober 2022 · Trifecta Study Demonstrates Prospera™ Kidney dd-cfDNA Test Outperforms DSA in Predicting Antibody Mediated Rejection · Persbericht

29 september 2022 · Natera Announces 2025 ESG Goals with Publication of 2021 Report · Persbericht

12 september 2022 · Natera Presents New Colorectal and Breast Cancer Data at ESMO 2022, Highlighting Signatera's Ability to Inform Treatment Decisions in the Adjuvant and Neoadjuvant Settings · Persbericht

6 september 2022 · Natera to Participate in Upcoming Investor Conferences · Persbericht

25 augustus 2022 · Natera Earns Great Place to Work Certification™ for Second Consecutive Year · Persbericht

11 augustus 2022 · Natera Announces Enrollment Completion for RenaCARE Study · Persbericht

Mijn selecties